Neonatal Life Support

Octubre - 2020


 

 

IV.-  Ventilación y Oxigenación
 

1.- Sustained Inflation (NRP 809: SysRev)


When a newborn does not breathe spontaneously, establishing functional residual capacity requires clearing the lung fluid and replacing it with air. Debate continues about the most effective method to achieve this. Animal studies suggest that a longer sustained inflation may be beneficial for short term respiratory outcomes, but most such studies were performed in intubated animal models. 51 It is unknown whether the same is true in newborn infants.52,53 In 2015, the NLS Task Force evaluated the evidence supporting use of sustained inflation for initiation of PPV in the delivery room and suggested against its routine use.1,9,10 Multiple clinical trials of sustained inflation have been published after that 2015 recommendation, prompting the NLS Task Force to request a 2020 SysRev.53a
 

Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Newborn infants who receive PPV due to bradycardia or ineffective respirations at birth

  • Intervention: Initiation of PPV with sustained inflation(s) more than 1 second

  • Comparator: Initiation of PPV with intermittent inflations, lasting 1 second or less per breath

  • Outcome21:

    • Primary: Death before discharge (critical)

    • Secondary:

      • Death in the delivery room (critical)

      • Death within first 48 hours (critical)

      • Need for mechanical ventilation during hospitalization (critical)

      • Air leaks (pneumothorax, pneumomediastinum, pneumopericardium, pulmonary interstitial emphysema) reported individually or as a composite outcome at any time during initial hospitalization and also within first 48 hours (critical)

      • Bronchopulmonary dysplasia, any grade,54 defined as need for supplemental oxygen at 28 days of life; need for supplemental oxygen at 36 weeks’ gestational age for infants born at or before 32 weeks of gestation (critical)

      • Intraventricular hemorrhage: Of any grade55 and Grade 3 or above (critical)

      • Retinopathy of prematurity: Of any stage56 and Stage 3 or above (critical)

      • Death by time of latest follow-up (critical)

      • Long-term neurodevelopmental or behavioral or education outcomes (greater than18 months of corrected age; test used to assess neurodevelopmental outcome should be of adequate quality and validated) (critical)

  • Study design: RCTs and nonrandomized studies (non- RCTs, interrupted time series, controlled before-andafter studies, cohort studies) were eligible for inclusion.

  • Time frame: All years and languages were included if there was an English abstract; unpublished studies (eg, conference abstracts, trial protocols) were excluded. Literature search was updated to October 25, 2019.  PROSPERO Registration: CRD 42020155639

 

A Priori Subgroup Analyses

  • Preterm infants at 28+0 weeks or less, 28 weeks and 1 day to 31 weeks and 6 days, 32 weeks to 36 weeks and 6 days, 37 weeks or more (term)

  • Duration of first sustained inflation:

    • 1 to 5 seconds, 6 to 15 seconds, greater than 15 seconds

  • Inflation pressure used during first sustained inflation :

    • 20 cm H2O or less, greater than 20 cm H2O

  • Interface or device used to generate sustained inflation  :

    • Nasopharyngeal tube, endotracheal tube, face mask, or T-piece device versus other device


A Priori Sensitivity Analyses

  • Effects of whether or not studies allowed multiple sustained inflations

  • Effects of the methodological quality of trials (to ascertain whether studies with high risk of bias overestimated treatment effects)


Consensus on Science


The SysRev identified 10 eligible RCTs including 1502 newborn infants. From analysis of this evidence, the NLS Task Force developed a draft CoSTR that was posted on the ILCOR website for a 2-week public commenting period beginning February 17, 2020. The Justification section was revised to address the public comments.

 

For the primary outcome of death before discharge, evidence of low certainty (downgraded for risk of bias and inconsistency) from 10 RCTs57–66 enrolling 1502 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed no significant benefit or harm from initiating PPV with sustained inflation greater than 1 second compared with initiating PPV with intermittent inflations lasting 1 second or less. See Table 2.


For the secondary critical long-term neurodevelopmental outcomes and death at latest follow-up, no studies were identified. The remainder of the secondary
outcomes are reported in
Table 2.

 

Table 2. Meta-analysis of RCTs Comparing Initiation of PPV With Sustained Inflation(s) Greater Than 1 Second Versus Initiation of PPV With Intermittent  Inflations, Last 1 Second or Less per Breath.

 


Subgroup Analysis for Primary Outcome


Subgroup Newborns Less Than 28+0 Weeks.

 

For the critical outcome of death before discharge, low-certainty evidence (downgraded for risk of bias and imprecision) from 5 RCTs57,58,61,62,65 enrolling 862 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed evidence of potential harm from initiating PPV with sustained inflation(s) greater than 1 second compared with initiating PPV with intermittent inflations lasting 1 second or less per breath (RR, 1.38; 95% CI, 1.00–1.91; I2, 0%; 46 more patients/1000 died before hospital discharge with sustained inflation(s) [0 fewer to 110 more per 1000]). The number needed to harm is 22 (95% CI, 9–1000 or greater).


Subgroup Newborns 28+1 Weeks to 31+6 Weeks of Age.


 For the critical outcome of death before discharge, very low-certainty evidence (downgraded for risk of bias and very serious imprecision) from 4 RCTs  57,61,62,66 enrolling 175 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed no significant benefit or harm from initiating PPV with sustained inflation(s) greater than 1 second when compared with initiating PPV with intermittent inflations lasting 1 second or less per breath (RR, 1.33; 95% CI, 0.22–8.20; I2, 5%; 4 more patients/1000 died before hospital discharge with sustained inflation(s) [9 fewer to 86 more per 1000]).
Subgroup Newborns 32+0 to 36+6 Weeks. No published data for this gestational age group were available. Subgroup Newborns 37+0 Weeks or More (Term).
No published data for this gestational age group were available.


Subgroup Analyses: by Duration of First Sustained Inflation or Inflation Pressure of the Sustained Inflation.   

 

For the critical outcome of death before discharge, subgroup analyses were conducted for the duration of the first sustained inflation (6–15 seconds versus greater than 15 seconds) and for the inspiratory pressure of the first sustained inflation with inspiratory pressure greater than 20 mm Hg versus 20 mm Hg or  less). For each of these subgroup analyses, the evidence was of very low certainty (downgraded for risk of bias in all cases and variously for imprecision, very serious imprecision, and inconsistency). None of the subgroup analyses showed any significant benefit or harm of sustained inflation when compared with initiating PPV with intermittent inflations lasting 1 second or less per breath.


These conclusions were based on 9 RCTs57–61,63–66 enrolling 1300 preterm newborns (sustained inflation 6–15 seconds), 2 RCTs 62,64 enrolling 222 preterm newborns (sustained inflation of greater than 15 seconds), 6 RCTs58–62,66 enrolling 803 preterm newborns (inspiratory pressure greater than 20 mm Hg), and 4 RCTs57,63–65 enrolling 699 preterm newborns (inspiratory pressure 20 mm Hg or less).


Sensitivity Analysis for Primary Outcome


Excluding Studies With High Risk of Bias. For the critical outcome of death before discharge, lowcertainty evidence (downgraded for risk of bias and
imprecision) from 9 RCTs 57–62,64–66  enrolling 1390 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed no significant
benefit or harm from initiating PPV with sustained inflation(s) greater than 1 second compared with initiating PPV with intermittent inflations lasting 1 second
or less per breath. (RR, 1.24; 95% CI, 0.92–1.68; I2, 24%; 21 more patients/1000 died before hospital discharge with sustained inflation(s) [95% CI, 7 fewer to
61 more per 1000]).

 

Excluding Studies That Allowed Only a Single Sustained Inflation During Resuscitation.

 

For the critical outcome of death before discharge, lowcertainty evidence (downgraded for risk of bias and imprecision) from 9 RCTs57–63,65,66 enrolling 1402 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed no significant benefit or harm from initiating PPV with sustained inflation greater than 1 second compared with initiating PPV with intermittent inflations lasting 1 second or less per breath (RR, 1.17; 95% CI, 0.88–1.55; I2, 22%; 18 more patients/1000 died before hospital discharge with sustained inflation(s) [95% CI, 13 fewer to 58 more per 1000]).


Sustained Inflation With Mask Only. When considering only studies where a face mask was used to deliver initial sustained inflation, for the critical outcome of death before discharge, low-certainty evidence (downgraded for risk of bias and imprecision from 9 RCTs58–66 enrolling 1441 preterm newborns who received PPV for bradycardia or ineffective respirations at birth showed no significant benefit or harm from initiating PPV with sustained inflation(s) greater than 1 second compared with initiating PPV with intermittent inflations lasting 1 second or less per breath (RR, 1.06; 95% CI, 0.61–1.39; I2, 42%; 7 more patients/1000 died before} hospital discharge with sustained inflations [95% CI, 44 fewer to 44 more per 1000]).
 

Treatment Recommendations

  • For preterm newborn infants who receive PPV for bradycardia or ineffective respirations at birth, we suggest against the routine use of initial sustained inflation(s) greater than 5 seconds (weak recommendation, lowcertainty evidence).

  • A sustained inflation may be considered in research settings. For term or late preterm infants who receive PPV for bradycardia or ineffective respirations at birth, it is not possible to recommend any specific duration for initial inflations due to the very low confidence in effect estimates.


Justification and Evidence-to-Decision Framework Highlights


This topic was prioritized by the NLS Task Force after completion of a large RCT65 published after the 2015 CoSTR.1,9,10 In making these recommendations, the
NLS Task Force considered the potential for increased death within 48 hours in preterm infants and increased death before discharge in preterm infants less than
28+0 weeks, a predefined subgroup of the systematic review.53a The task force recognizes that the outcome of death within 48 hours was influenced primarily by
1 study for which death within 48 hours was one of multiple secondary outcomes.65 The NLS Task Force also considered the absence of evidence for either  benefit or harm after sustained inflation at birth for all other critical and important outcomes.


The study comparisons were compromised by methodological heterogeneity across studies, including indication, duration, the use of different inspiratory pressures during sustained inflation and different inflation durations. No study was identified comparing short duration sustained inflation (less than 5 seconds) with intermittent inflations by using inspiratory time of 1 second or less. There is no new evidence to support or refute the practice of inflations less than 5 seconds immediately after birth.

 

Hunt et al67 was excluded from this systematic review because the control group received short duration sustained inflations (5 inflations of 2–3 seconds each) and the intervention group received sustained inflations of 15 seconds duration (and thus did not meet predefined inflation duration criteria for the comparator group).
A patent airway is necessary for effective lung inflation or ventilation. A recent study demonstrated that preterm rabbit pups are prone to closure of the larynx
(ie, it opens only briefly during a spontaneous breath); this impedes noninvasive PPV after birth.53 Studies in preterm infants have shown that very little gas enters
the lungs in the absence of spontaneous breathing, suggesting that the same phenomenon occurs in preterm infants.68,69

 

This SysRev53a (and most studies it identified) focused on use of sustained inflation in newborns who are not breathing effectively, so inadequate laryngeal patency could explain the absence of benefit from sustained inflation immediately after birth in preterm infants. In addition, the NLS Task Force noted that the trials included in the systematic review were pragmatic in design and did not include respiratory function monitors to assess actual pressure and volume delivered or the actual duration of the sustained inflation. It remains unknown if mask leak or airway obstruction influenced the effectiveness of the sustained inflations. This further decreases the confidence in the effect estimates, especially for the subgroup analyses. See Supplement Appendix A-2 for the evidence-todecision table for this SysRev.


Knowledge Gaps
 

  • How much of a role does glottis closure play in determining the effectiveness of sustained inflation in newborn of different gestational ages ?

  • What is the optimal duration, optimal inspiratory pressure, and number of sustained inflation maneuvers that allow establishment of functional
    residual capacity without barotrauma ?

  • The NLS Task Force recognizes that the total number of infants studied thus far is insufficient to have confidence in the estimate of effect. Larger
    multicenter trials are needed in both term and preterm newborns to determine whether there are benefits or harms from sustained inflations.

  • Studies comparing short duration sustained inflation (less than 5 seconds) with intermittent inflations (inspiratory time 1 second or less) are needed. This is an important knowledge gap as the European Resuscitation Council currently recommends using inflations of a 2- to 3-second
    duration for the first 5 breaths in infants who are  gasping or not breathing.

  • Is there a role for sustained inflation for other situations in resuscitation, such as during cardiac compressions ?

  • (For more detail, see EvUp for NLS 895 CPR Ratios)


2.-  PEEP Versus No PEEP (NLS 897: EvUp)


During resuscitation after birth, PPV is provided to inflate and ventilate the lungs. The lungs of sick or preterm newborns tend to collapse as they are not supported
by a stiff chest wall and the infant’s breathing efforts may be weak; the lungs may also be immature and surfactant- deficient.70 PEEP provides low positive pressure to the airway, which helps prevent lung collapse at the end of expiration. PEEP maintains lung volume during PPV in animal studies and improves lung function and oxygenation.71,72 PEEP may be beneficial during neonatal resuscitation, but the evidence from human studies is limited. The previously reported evidence for use of PEEP was evaluated as part of the 2015 CoSTR for NLS.1,9,10


In 2020, The NLS Task Force undertook an EvUp to determine whether additional evidence published after 2015 warranted consideration of a new SysRev.
The evidence update (see Supplement Appendix C-4) identified no evidence that would suggest the need for a new SysRev or a change in the 2015 treatment recommendation. 1,9,10 Most of the new studies identified confirm the 2015 recommendation for use of PEEP during PPV in the delivery room.
 

Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Preterm/term newborn infants who do not establish spontaneous respiration at birth

  • Intervention: Use of PEEP as part of the initial ventilation strategy

  • Comparator: No PEEP

  • Outcome21:

    • Survival to discharge (critical)

    • 5-minute Apgar scores (important)

    • Time for heart rate to rise above 100/min (important)

    • Intubation rate in the delivery room (important)

    • Chest compressions in the delivery room (important)

    • Incidence of air leaks (important)

    • Oxygen saturation/oxygenation (important)

    • Fio2 exposure in the delivery room (important)

    • Mechanical ventilation in the first 72 hours (important)

    • Bronchopulmonary dysplasia (any) (important)


Treatment Recommendation

  • This treatment recommendation has not changed from 2015.1,9,10

  • We suggest using PEEP for the initial ventilation of premature newborn infants during delivery room resuscitation (weak recommendation, low-quality evidence).

  • We cannot make any recommendation for term infants because of insufficient data.


3.- CPAP Versus Intermittent Positive Pressure Ventilation (NLS 590: EvUp)


Newborn infants who breathe spontaneously need to establish a functional residual capacity after birth.73 Some newborn infants experience respiratory distress,
which manifests as labored breathing or persistent cyanosis. Continuous positive airway pressure (CPAP), a form of respiratory support, helps prevent atelectasis in newborns. CPAP is especially helpful for preterm newborn infants with breathing difficulty after birth or after resuscitation.74 CPAP may also reduce the risk of death or bronchopulmonary dysplasia in very preterm infants when compared with endotracheal intubation and PPV.75–79 For the newborn infant, CPAP is a less- invasive form of respiratory support than intubation and PPV.

 

Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Spontaneously breathing preterm newborn infants with respiratory distress requiring respiratory support in the delivery room

  • Intervention: CPAP

  • Comparator: Intubation and intermittent PPV

  • Outcome21:

    • Death or bronchopulmonary dysplasia (critical)

    • Death (critical)

    • Bronchopulmonary dysplasia54 (important)

    • Air leak (important)

    • Necrotizing enterocolitis (important)

    • Severe intraventricular hemorrhage55 (critical)

    • Severe retinopathy of prematurity56 (critical)

This topic was last reviewed in the 2015 CoSTR.1,9,10 The NLS Task Force sought an EvUp to identify any studies published after the 2015 CoSTR. The EvUp did not identify any new studies that would potentially change the current recommendation. The 2015 CoSTR treatment recommendation remains in effect.1,9,10
The entire EvUp can be reviewed in Supplement Appendix C-5.


Treatment Recommendations

  • This treatment recommendation (below) is unchanged from 2010.1,9,10

  • For spontaneously breathing preterm newborn infants with respiratory distress requiring respiratory support in the delivery room, we suggest initial use of CPAP rather than intubation and intermittent PPV (weak recommendation, moderate certainly of evidence).

 

4.- T-Piece Resuscitator Versus Self-Inflating Bag for Ventilation (NLS 870: ScopRev)


Rationale for Review


In 2015, the ILCOR Neonatal Task Force published a CoSTR summarizing the evidence comparing the use of a T-piece resuscitator with the use of a self-inflating bag for newborns receiving ventilation during resuscitation. 1,9,10 The studies reviewed for the 2015 CoSTR noted that the use of T-piece resuscitators demonstrated marginal but not statistically significant benefits for the clinical outcome of achieving spontaneous breathing.


The NLS Task Force decided to reevaluate this topic through a ScopRev79a to determine whether sufficient new evidence had been published after the 2015 CoSTR1,9,10 to justify a new SysRev.
 

Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Newborn infants receiving ventilation (PPV) during resuscitation

  • Intervention: T-piece resuscitator

  • Comparator: Self-inflating bag

  • Outcome21:

    • Survival to hospital discharge (critical)

    • Air leak (important)

    • Development of stable spontaneous breathing (no need for intubation in delivery room) (important)

    • Bronchopulmonary dysplasia (any) (important)

  • Study design: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled before-and-after studies, cohort studies) are eligible for inclusion.

  • Time frame: All years and languages were included if there was an English abstract; unpublished studies (eg, conference abstracts, trial protocols) were excluded. Literature search was updated to January 3, 2020.


Summary of Evidence
 

Using the 2015 search strategy, this ScopRev79a identified 2 additional studies: 1 RCT80 and 1 observational study81 published after the review for the 2015 CoSTR was completed. When these 2 studies were added to the 2 studies identified in the 2015 CoSTR for NLS,1,9,10 a total of 4 clinical studies could be included in the data analysis, representing a total of 2889 newborns (927 in 3 RCTs and 1962 in 1 observational study).80–83


The 4 studies investigated different populations; 2 studies included term and preterm infants,80,83 and 2 studies enrolled preterm infants only.81,82 The studies also differed in reported outcomes and were from diverse geographical areas. The large observational study found that use of a T-piece resuscitator increased survival and decreased bronchopulmonary dysplasia and intubation in the delivery  room.81 The latest RCT also found decreased intubation in the delivery room when T-piece resuscitators were used.80 The ScopRev can be reviewed in its entirety in Supplement Appendix B-3.


Task Force Insights
 

Data from a substantial number of additional patients reported in 1 RCT and 1 large observational study suggest improved survival, less need for intubation, and a lower incidence of bronchopulmonary dysplasia when a T-piece resuscitator is used (compared with a self-inflating resuscitator bag) during PPV at birth, particularly in preterm infants.

 

The NLS Task Force concludes that these findings justify a new SysRev of the use of a T-piece resuscitator versus self-inflating bag for administering PPV at birth. The task force anticipates that not only the strength, but the direction of evidence may be changing toward support for using T-piece devices. Until a new SysRev is completed and results are analyzed by the NLS Task Force, the 2015 treatment recommendation remains in effect.1,9,10

 

Treatment Recommendation

  • This treatment recommendation (below) is unchanged from 2010.1,9,10

  • There is insufficient evidence regarding the use of T-piece resuscitator or self-inflating bag for initial PPV at birth, so the recommendation of one device over another would be purely speculative because the confidence in effect estimates is so low.
     

5.- Oxygen for Preterm Resuscitation (NLS 864: 2019 CoSTR)
 

Preterm newborn infants are vulnerable to oxidative stress as a result of reduced antioxidant defenses and  frequent exposure to oxygen during stabilization in the
delivery room.84 Many common preterm morbidities, such as bronchopulmonary dysplasia, retinopathy of prematurity and intraventricular hemorrhage are directly
associated with oxygen toxicity. In the delivery room, it is imperative that clinicians prevent hypoxia while limiting hyperoxia. In 2019, the NLS Task Force published a SysRev with meta-analysis of the relevant available evidence on this topic,85 and published an ILCOR CoSTR statement.86,87
 

Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Preterm newborn infants (less than 35 weeks’ estimated gestational age) who receive respiratory support at birth

  • Intervention: Lower initial oxygen concentration (50% or less O2)

  • Comparator: Higher initial oxygen concentration (more than 50% O2)

  • Outcome21 :

    • Primary: All-cause short-term mortality (in hospital or 30 days) (critical)

    • Secondary:

      • All-cause long-term mortality (1–3 years) (critical)

      • Long-term NDI (1–3 years) (critical)

      • Retinopathy of prematurity (Stages III–V)56 (critical)

      • Necrotizing enterocolitis Stage II (pneumatosis) or III (surgical)88 (important)

      • Bronchopulmonary dysplasia (moderate to severe)54 (critical)

      • Major intraventricular hemorrhage (Grade III–IV)55 (critical)

      • Time to heart rate more than 100/min (important)

  • Study design: RCTs, quasi-RCTs and nonrandomized studies included; animal studies, unpublished studies, and published abstracts (eg, conference abstracts) excluded

  • Time frame: Literature search was from 1980 to August 10, 2018.

  • PROSPERO Registration: CRD42018084902

Treatment Recommendations

  • This treatment recommendation (below) is unchanged from 2019.86,87

  • For preterm newborn infants (less than 35 weeks’ gestation) who receive respiratory support at birth, we suggest starting with a lower oxygen concentration (21% to 30%) rather than higher initial oxygen concentration (60% to 100%) (weak recommendation, very low-certainty evidence).

  • We suggest the range of 21% to 30% oxygen because all trials used this for the low oxygen concentration group.

  • Subsequent titration of oxygen concentration using pulse oximetry is advised (weak recommendation, very low-certainty evidence).


6.- Oxygen for Term Resuscitation (NLS 1554: 2019 CoSTR)


Administration of high oxygen concentrations leads to free radical formation and may be toxic to many tissues and organs of the newborn. Questions persist about the risks of hypoxia versus risks of exposure to excess oxygen for late preterm and term newborn infants who receive respiratory support in the delivery room. In 2019, the NLS Task Force published a SysRev with meta-analysis of the relevant available evidence on this topic89 and also published an NLS CoSTR.86,87 For complete review of the consensus on science for the secondary outcomes and subgroup analyses, please see the NLS Task Force section of the recently published 2019 CoSTR summary.86,87


Population, Intervention, Comparator, Outcome, Study Design, and Time Frame

  • Population: Newborn infants (35 weeks’ or greater gestation) who receive respiratory support at birth

  • Intervention: Lower initial oxygen concentration (50% O2 or less)

  • Comparator: Higher initial oxygen concentration (greater than 50% O2)

  • Outcome21:

    • Primary: All-cause short-term mortality (in hospital or 30 days) (critical)

    • Secondary: All-cause long-term mortality (1–3 years) (critical)

    • Long-term NDI (1–3 years) (critical)

    • HIE (Sarnat Stage 2–3)90 (critical)

  • Study design: RCTs, quasi-RCTs, and nonrandomized studies included; animal studies, unpublished studies, and published abstracts (eg, conference abstracts) excluded

  • Time frame: Literature search was from 1980 to August 10, 2018.

  • PROSPERO Registration: CRD42018084902

Treatment Recommendations

  • This treatment recommendation (below) is unchanged from 2019.86,87

  • For newborn infants at 35 weeks’ or greater gestation receiving respiratory support at birth, we suggest starting with 21% oxygen (air) (weak recommendation, low certainty of evidence).

  • We recommend against starting with 100% oxygen (strong recommendation, low certainty of evidence).